JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
After double lung transplantation, he was discharged without supplemental oxygen on the eleventh day
10 implementation focused initiatives recommended to accelerate policy reforms, standardization of home care delivery services, and improve accessibility and affordability of care in tier II and tier III geographies
Biogen paid Ionis a US $ 60 million one-time upfront payment
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
Partnering to build biosynthesis processes and a pharmaceutical production platform
Oravax's oral VLP vaccine in development targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the vaccine potentially more effective against current and future variants of the Covid-19 virus
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
Subscribe To Our Newsletter & Stay Updated
